Guest: Dr Michael Freeman
Presenter: Wayne Bucklar
Guest Bio: Dr Michael Freeman is the principal Dermatologist at The Skin Centre, specialising in Cosmetic and Laser Dermatology. He has more than 30 years’ experience in the medical field. In addition to his position at The Skin Centre, Dr Freeman is the Director of Dermatology at the Gold Coast Hospital, a visiting Dermatologist at the Princess Alexandra Hospital in Brisbane, and is an Associate Professor of Dermatology at Bond University. He is also a member of the Skin and Cancer Foundation of Queensland and an international member of the American Academy of Dermatology. Dr Freeman holds several more credits to his name, including lead investigator in more than a dozen clinical trials, and educator for other Dermatologists in the use of specialised lasers. In his spare time, Dr Freeman is a passionate sailor.
Segment overview: In today’s Health Supplier Segment, let us learn more about the double-blind RCT conducted by researchers at University of Sydney from 2012 tp 214 with 386 patients who had experienced two or more previous Non-Melanoma Skin Cancers in the past five years. The researchers found patients taking Nicotinamide 500mg twice daily for one year showed a 23 percent reduction in new diagnoses on NMSC, compared with those taking a placebo. Our guest The Skin Centre principal Dermatologist Dr Michael Freeman discusses the results of the research that show promise to cut the risk of new skin cancer s in the coming years. The specialised nicotinamide product used in the study was developed by Australian natural healthcare company Blackmores.

Guest: Professor Peter Howe